Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

• Published in: Clinical cancer research Vol. 14; no. 11; pp. 3268 - 3277
• Main Authors: SHOEMAKER, Alex R, MITTEN, Michael J, BAUCH, Joy, MARSH, Kennan, TAHIR, Steven K, XIUFENYANG, TSE, Christin, FESIK, Stephen W, ROSENBERG, Saul H, ELMORE, Steven W, ADICKES, Jessica, ACKLER, Scott, REFICI, Marion, FERGUSON, Debra, OLEKSIJEW, Anatol, O'CONNOR, Jacqueline M, BAOLE WANG, FROST, David J
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.06.2008
• Subjects: ABT-263; Aniline Compounds - administration & dosage; Animals; Antineoplastic agents; Antineoplastic Agents - administration & dosage; apoptosis; Bcl-2; Biological and medical sciences; Carcinoma, Small Cell - drug therapy; Dose-Response Relationship, Drug; Humans; Lung Neoplasms - drug therapy; Medical sciences; Mice; Mice, Nude; Pharmacology. Drug treatments; Pneumology; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors; Proto-Oncogene Proteins c-bcl-2 - drug effects; small cell lung cancer; Sulfonamides - administration & dosage; Tumors of the respiratory system and mediastinum; xenograft; Xenograft Model Antitumor Assays; Lung disease; Respiratory disease; Animal; Lung cancer; Bonchopulmonary small cell carcinoma; C-Onc gene; Bronchus disease; Inhibitor; Malignant tumor; Biological activity; Protooncogene; Cancer

Purpose: The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models. Experimental Design: A panel of 11 SCLC xenograft models was established to evaluate the efficacy of ABT-263. Single agent a...